Qiming Venture Partners, a Chinese venture capital firm, announced that David Chu joined the firm as a Partner, focusing on fundraising and investor relations for the firm’s USD funds.
Chu has extensive experience in fund management and investment. He has over 20 years of experience in the venture capital ecosystem as a limited partner, financial advisor to entrepreneurs, and venture capitalist. Prior to joining Qiming, Chu spent seven years in a limited partner role where he served on 30 advisory boards and led over $2.5 billion in approved commitments across numerous PE/VC funds, co-investments, and secondaries.
Founded in 2006, Qiming Venture Partners is a venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.
Currently, Qiming Venture Partners manages ten US Dollar funds and six RMB funds with $6.2 billion in AUM capital raised. Since its establishment, the firm has invested in companies in the TMT and healthcare industries at the early and growth stages.
Since our debut, the Qiming has backed over 430 fast-growing and innovative companies. Over 170 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 40 portfolio companies that have achieved unicorn status.
Many of its portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many others.
FinSMEs
06/03/2022